

Evaluating sequential processing of A β by γ -secretase in cell culture models

Yong Ran, Pedro E. Cruz, Thomas B. Ladd, Brenda Moore, Kevin M. Felsenstein and Todd E. Golde

Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience, University of Florida, Gainesville, Florida

Understanding how different species of A β are generated and how β -secretase can be modulated has broad therapeutic implications for AD, as shifts in β -secretase processing increasing the relative production of A β 42 can cause Alzheimer's disease (AD). We further explored the tri-peptide cleavage model proposed by Ihara and colleagues using BRI2-A β fusion proteins. We generated BRI2-A β proteins spanning from A β 1-37 to A β 1-55 and C99. Each of these 21 constructs were transfected into cells and A β production assessed. Both secreted A β and cell associated A β were detected using ELISA and IP/MS. In addition effects of β -secretase inhibitors (GSIs) on A β production was examined. BRI2 fusion proteins expressing A β 47 or smaller A β s were not significantly processed by β -secretase, though A β peptides were readily detected in the cells and media. A β 48 was processed by β -secretase but almost exclusively produced species other than A β 40 or 42. A β peptides longer than A β 48 were efficiently cleaved by β -secretase and produced varying ratios of A β 40:42. Most notably A β 51 produced the greatest shift towards A β 42 production. IP/MS studies are underway to define the profiles of A β produced from these constructs, including those delivered to the mouse brain using rAAV vectors. Truncated substrates dramatically increased the IC50s of multiple GSIs relative to APP in some cases from sub nanomolar to micromolar levels. A wealth of observations regarding fate and properties of these longer A β peptides will provide crucial information regarding their biological and disease relevance.

Biography

Dr. Yong Ran got his Ph.D from Huazhong University of Science and Technology, China, in 2004. His postdoctoral studies at the University of Florida (2006-2010) were focused on lipid transfer proteins. Currently he is an Assistant Scientist of the Center for Translational Research in Neurodegenerative Disease at University of Florida.

yrn@ufl.edu